Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06617325 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
A Phase 3 study of Systemic Lupus Erythematosus, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT06617325 is a Phase 3 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 450 participants, above the 376-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT06617325, a Phase 3 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG DZP
Study Locations (20)
California
- Sl0044 50737 - Beverly Hills
- Sl0044 50257 - La Jolla
- Sl0044 50275 - La Palma
- Sl0044 50755 - Los Alamitos
- Sl0044 50258 - Los Angeles
- Sl0044 50725 - Menifee
- Sl0044 50340 - Orange
- Sl0044 50316 - San Leandro
Arizona
- Sl0044 50058 - Avondale
- Sl0044 50550 - Chandler
- Sl0044 50713 - Gilbert
- Sl0044 50662 - Glendale
- Sl0044 50052 - Phoenix
Florida
- Sl0044 50239 - Brandon
- Sl0044 50630 - Clearwater
- Sl0044 50747 - Coral Gables
- Sl0044 50751 - Coral Gables
- Sl0044 50362 - Gainesville
Arkansas
- Sl0044 50670 - Searcy
Colorado
- Sl0044 50719 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06617325
The ClinicalTrials.gov registry entry for NCT06617325 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 376-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (20% higher). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06617325 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06617325 about?
NCT06617325 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus". The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
What is the current status of trial NCT06617325?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2024-11-21. Estimated completion is 2028-05-31.
What conditions does trial NCT06617325 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT06617325?
The interventions under investigation include: Placebo (OTHER), DZP (DRUG).
Who is sponsoring clinical trial NCT06617325?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06617325 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RECRUITING · Phase 3
-
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RECRUITING · Phase 3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.